Condition
Breast Implant-Associated Anaplastic Large Cell Lymphoma
Total Trials
3
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Recruiting2
Unknown1
Clinical Trials (3)
Showing 3 of 3 trials
NCT01793168Recruiting
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
NCT05978141Recruiting
A Registry for People With T-cell Lymphoma
NCT05017337UnknownPrimary
Breast-implant ASsocIated anaplastIc Large Cell Lymphoma and CApsular Contracture
Showing all 3 trials